Welcome to the international HTA database

Showing [23537 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2022	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Efficacy and safety of transanal irrigation in adults with bowel dysfunction]
2022	National Institute for Health and Care Excellence (NICE)	Daratumumab monotherapy for treating relapsed and refractory multiple myeloma. NICE technology appraisal guidance 783
2022	Canadian Agency for Drugs and Technologies in Health (CADTH)	Internet-delivered cognitive behavioural therapy in the treatment of chronic non-cancer pain
2022	WorkSafeBC	Satir brief transformational therapy as treatment for trauma-related disorders including PTSD
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: assessment of the relevance of tandem mass spectrometry-based newborn blood spot screening for argininosuccinic aciduria (ASA)]
2022	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Systematic review on diagnosis and care of reactive attachment disorder]
2022	National Institute for Health and Care Excellence (NICE)	Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer. NICE technology appraisal guidance 784
2022	Canadian Agency for Drugs and Technologies in Health (CADTH)	Intraocular lens implantation for infants with aphakia: a systematic review of clinical effectiveness and cost-effectiveness
2022	National Institute for Health and Care Excellence (NICE)	Nivolumab with cabozantinib for untreated advanced renal cell carcinoma (terminated appraisal). NICE technology appraisal guidance 785
2022	Norwegian Institute of Public Health (NIPH)	[Intravenous ketamine for treatment-resistant depression and suicidal ideation: a single technology assessment - mapping]
2022	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Safety and effectiveness of percutaneous tricuspid valve repair]
2022	National Institute for Health and Care Excellence (NICE)	Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies. NICE technology appraisal guidance 786
2022	NIHR Health Technology Assessment programme	The Best Services Trial (BeST?): Effectiveness and cost-effectiveness of the New Orleans Intervention Model for Infant Mental Health
2022	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	[Effectiveness of social distancing measures, in the context of the COVID-19]
2022	National Institute for Health and Care Excellence (NICE)	Venetoclax with low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable. NICE technology appraisal guidance 787
2022	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Occupational exposures and asthma and COPD]
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Treprostinil in chronic thromboembolic pulmonary hypertension (group 4)]
2022	The Regional Health Technology Assessment Centre (HTA-centrum)	Osseointegrated upper limb prostheses with and without neuromuscular control: benefits and risks
2022	National Institute for Health and Care Excellence (NICE)	Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy. NICE technology appraisal guidance 788
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Irreversible electroporation in pancreatic cancer]
2022	The Regional Health Technology Assessment Centre (HTA-centrum)	[Benefits and risks of caseload midwifery: continuity of midwifery team during antenatal, intrapartal, and postnatal care]
2022	National Institute for Health and Care Excellence (NICE)	Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations. NICE technology appraisal guidance 789
2022	NIHR Health Technology Assessment programme	A rapid intrapartum test for group B Streptococcus to reduce antibiotic usage in mothers with risk factors: the GBS2 cluster RCT
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: integration of real-world data and evidence into assessments to support decision-making in the pharmaceutical sector]
2022	Austrian Institute for Health Technology Assessment (AIHTA)	Quality registries in dementia care: mapping of registries to improve quality and service delivery
2022	Institute for Clinical Effectiveness and Health Policy (IECS)	[Digital breast tomosynthesis]
2022	The Regional Health Technology Assessment Centre (HTA-centrum)	Active or semi-active robotic arm-assisted versus manual knee arthroplasty: benefits and risks
2022	National Institute for Health and Care Excellence (NICE)	TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices (terminated appraisal). NICE technology appraisal guidance 790
2022	Penn Medicine Center for Evidence-based Practice (CEP)	Medications for treating moderate to severe alcohol withdrawal syndrome in critical care and emergency department patients
2022	Malaysian Health Technology Assessment (MaHTAS)	Molecular profiling assays in early breast cancer
2022	The Regional Health Technology Assessment Centre (HTA-centrum)	Effectiveness and safety of surgical procedures to treat apical prolapse - comparison of sacrospinous fixation, laparoscopic sacrocolpopexy/sacrohysteropexy, and the Manchester procedure
2022	National Institute for Health and Care Excellence (NICE)	Romosozumab for treating severe osteoporosis. NICE technology appraisal guidance 791
2022	Penn Medicine Center for Evidence-based Practice (CEP)	Guidelines and clinical pathways for management of upper GI bleeding
2022	Malaysian Health Technology Assessment (MaHTAS)	Immunotherapy for PD-L1 positive advanced non-small cell lung cancer
2022	National Institute for Health and Care Excellence (NICE)	Filgotinib for treating moderately to severely active ulcerative colitis. NICE technology appraisal guidance 792
2022	NIHR Health Technology Assessment programme	Assessing the efficacy and safety of methotrexate vs ciclosporin in the treatment of severe atopic eczema in children: the TREatment of severe Atopic eczema in children Taskforce (TREAT) randomised controlled trial
2022	Penn Medicine Center for Evidence-based Practice (CEP)	Peripartum or postnatal care disparities and equity
2022	Malaysian Health Technology Assessment (MaHTAS)	Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) for non-small cell lung cancer
2022	National Institute for Health and Care Excellence (NICE)	Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus (terminated appraisal). NICE technology appraisal guidance 793
2022	NIHR Health Technology Assessment programme	EarlyCDT Lung blood test for risk classification of solid pulmonary nodules: systematic review and economic evaluation
2022	Malaysian Health Technology Assessment (MaHTAS)	Robotic arm-assisted surgery in total hip arthroplasty, total knee arthroplasty and unicompartmental knee arthroplasty
2022	National Institute for Health and Care Excellence (NICE)	Diroximel fumarate for treating relapsing–remitting multiple sclerosis. NICE technology appraisal guidance 794
2022	WorkSafeBC	Clinical accuracy of rapid antigen tests for COVID-19
2022	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Ambulatory blood pressure monitoring (ABPM) in the identification of circadian patterns in patients with arterial hypertension: evaluation of safety, effectiveness, and efficiency]
2022	National Institute for Health and Care Excellence (NICE)	Ibrutinib for treating Waldenstrom's macroglobulinaemia. NICE technology appraisal guidance 795
2022	Penn Medicine Center for Evidence-based Practice (CEP)	Workplace violence in healthcare settings
2022	WorkSafeBC	Functional neurology as treatment for post-traumatic brain injury
2022	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Evaluation of the safety, efficacy/effectiveness, and efficiency of teleconsultation in primary care, and the organizational, ethical, social, and legal aspects linked to its use]
2022	National Institute for Health and Care Excellence (NICE)	Venetoclax for treating chronic lymphocytic leukaemia. NICE technology appraisal guidance 796
2022	Health Technology Wales (HTW)	Electronic blood management systems for blood transfusions
2022	WorkSafeBC	Dupuytren's contracture and wrist fractures
2022	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Evaluation of the safety, efficacy/effectiveness, and efficiency of stereotactic body radiation therapy (SBRT) in lung, prostate, and liver cancer]
2022	National Institute for Health and Care Excellence (NICE)	Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal). NICE technology appraisal guidance 797
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: evaluation of Synvisc and Synvisc One for the management of knee osteoarthritis]
2022	WorkSafeBC	Percussion therapy for neuropathic pain
2022	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Stereotactic radiosurgery for the treatment of epilepsy, essential tremor, Parkinson's disease, glossopharyngeal and trigeminal neuralgia: synthesis of its efficacy, effectiveness, safety, and efficiency]
2022	National Authority for Assessment and Accreditation in Healthcare (INEAS)	[SKYRIZI® (Risankizumab) for the treatment of moderate to severe plaque psoriasis in adults : A rapid review]
2022	National Institute for Health and Care Excellence (NICE)	Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation. NICE technology appraisal guidance 798
2022	NIHR Health Technology Assessment programme	Coenzyme Q10 to manage chronic heart failure with a reduced ejection fraction: a systematic review and economic evaluation
2022	WorkSafeBC	Ketamine infusion therapy for hyperalgesia and or central sensitivity pain
2022	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Primary bariatric endoscopic techniques in adults with or without type 2 diabetes mellitus. Efficacy, effectiveness, and safety]
2022	National Institute for Health and Care Excellence (NICE)	Faricimab for treating diabetic macular oedema. NICE technology appraisal guidance 799
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[Guides and standards: use of electrodiagnostic testing in the neurological investigation - electromyography and nerve conduction studies]
2022	National Institute for Health and Care Excellence (NICE)	Faricimab for treating wet age-related macular degeneration. NICE technology appraisal guidance 800
2022	Health Technology Wales (HTW)	Stereotactic ablative radiotherapy (SABR) for the treatment of renal cell carcinoma
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: KamRAB (human rabies immunoglobulin) – passive and transient postexposure prophylaxis of rabies infection]
2022	National Institute for Health and Care Excellence (NICE)	Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancer. NICE technology appraisal guidance 801
2022	NIHR Health Technology Assessment programme	Oral nutritional interventions in frail older people who are malnourished or at risk of malnutrition: a systematic review
2022	National Institute for Health and Care Excellence (NICE)	Cemiplimab for treating advanced cutaneous squamous cell carcinoma. NICE technology appraisal guidance 802
2022	NIHR Health Technology Assessment programme	Determining optimal strategies for primary prevention of cardiovascular disease: systematic review of cost-effectiveness analyses in the United Kingdom
2022	National Institute for Health and Care Excellence (NICE)	Risankizumab for treating active psoriatic arthritis after inadequate response to DMARDs. NICE technology appraisal guidance 803
2022	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Home enteral nutrition in older patients with severe protein-energy malnutrition after hip fracture]
2022	NIHR Health Services and Delivery Research programme	Understanding the potential factors affecting carers’ mental health during end-of-life home care: a meta synthesis of the research literature
2022	National Institute for Health and Care Excellence (NICE)	Teduglutide for treating short bowel syndrome. NICE technology appraisal guidance 804
2022	NIHR Health Technology Assessment programme	Shock-absorbing flooring for fall-related injury prevention in older adults and staff in hospitals and care homes: the SAFEST systematic review
2022	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Conductive intravesical chemohyperthermia with mitomycin in non-muscle invasive bladder cancer: review of guidelines and ongoing research]
2022	National Institute for Health and Care Excellence (NICE)	Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in people with raised triglycerides. NICE technology appraisal guidance 805
2022	NIHR Health Technology Assessment programme	Endovascular stent grafting and open surgical replacement for chronic thoracic aortic aneurysms: a systematic review and prospective cohort study
2022	National Institute for Health and Care Excellence (NICE)	Belimumab for treating lupus nephritis (terminated appraisal). NICE technology appraisal guidance 806
2022	Scottish Health Technologies Group (SHTG)	Closed loop systems and the artificial pancreas for type I diabetes mellitus (T1DM)
2022	Austrian Institute for Health Technology Assessment (AIHTA)	Perinatal and infant mental health care models and pathways
2022	WorkSafeBC	Environmental exposure to respirable particles and estimated risk of sarcoidosis
2022	National Institute for Health and Care Excellence (NICE)	Roxadustat for treating symptomatic anaemia in chronic kidney disease. NICE technology appraisal guidance 807
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: next-generation sequencing (NGS) panels for muscle disease]
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Ixazomib (reassessment after the deadline: multiple myeloma, at least 1 prior therapy, combination with lenalidomide and dexamethasone)]
2022	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Assessment and clinical management of self-harm in adolescence: evidence-based protocol]
2022	WorkSafeBC	Tinnitus and the COVID-19 vaccine
2022	Agency for Healthcare Research and Quality (AHRQ)	Acute treatments for episodic migraine
2022	National Institute for Health and Care Excellence (NICE)	Fenfluramine for treating seizures associated with Dravet syndrome. NICE technology appraisal guidance 808
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[Report: detection of Chlamydia trachomatis, Neisseria gonorrhoeae and Trichomonas vaginalis by NAAT]
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Delamanid (repeal of the exemption: pulmonary multi-drug resistant tuberculosis, ≥ 10 kg)]
2022	Malaysian Health Technology Assessment (MaHTAS)	Early cancer detection test for lung (EarlyCDT-Lung)
2022	WorkSafeBC	Vision therapy as treatment for traumatic brain injury: 2022 update
2022	National Institute for Health and Care Excellence (NICE)	Imlifidase for desensitisation treatment before kidney transplant in people with chronic kidney disease. NICE technology appraisal guidance 809
2022	Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS)	[The use of social media and electronic communication in the delivery of youth protection services to young people in difficulty and their families]
2022	NIHR Health Services and Delivery Research programme	Safety of disinvestment in mid- to late-term follow-up post primary hip and knee replacement: the UK SAFE evidence synthesis and recommendations
2022	Health Technology Wales (HTW)	Laryngeal biopsies in the outpatient setting in people with suspected head and neck dysplasia/cancer
2022	WorkSafeBC	Inpatient versus outpatient programs as treatment for PTSD
2022	National Institute for Health and Care Excellence (NICE)	Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence. NICE technology appraisal guidance 810
2022	NIHR Health Technology Assessment programme	Biomarkers for assessing acute kidney injury for people who are being considered for admission to critical care: a systematic review and cost-effectiveness analysis